Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKinsey
Mallinckrodt
Baxter
Dow
AstraZeneca
Merck

Last Updated: November 19, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Sym004

See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Sym004?

Sym004 is an investigational drug.

There have been 11 clinical trials for Sym004. The most recent clinical trial was a Phase 2 trial, which was initiated on February 1st 2019.

The most common disease conditions in clinical trials are Colorectal Neoplasms, Carcinoma, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are Symphogen A/S, Annick Desjardins, and EMD Serono.

There are two US patents protecting this investigational drug and thirty-two international patents.

Recent Clinical Trials for Sym004
TitleSponsorPhase
Sym004 Versus TAS-102 in Patients With mCRCSymphogen A/SPhase 3
Sym004 Versus Futuximab or Modotuximab in Patients With mCRCSymphogen A/SPhase 2
Sym004 in Metastatic Colorectal Cancer and ECD-EGFR PatientsSymphogen A/SPhase 2

See all Sym004 clinical trials

Clinical Trial Summary for Sym004

Top disease conditions for Sym004
Top clinical trial sponsors for Sym004

See all Sym004 clinical trials

US Patents for Sym004

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Sym004   Start Trial Binding molecules specific for HER3 and uses thereof MEDIMMUNE, LLC (Gaithersburg, MD)   Start Trial
Sym004   Start Trial Methods for assessing and identifying or evolving conditionally active therapeutic proteins Halozyme, Inc. (San Diego, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Sym004

Drugname Country Document Number Estimated Expiration Related US Patent
Sym004 Australia 2012340766 2031-11-23   Start Trial
Sym004 Brazil 112014012539 2031-11-23   Start Trial
Sym004 Canada 2856297 2031-11-23   Start Trial
Sym004 China 104093743 2031-11-23   Start Trial
Sym004 China 108424456 2031-11-23   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Baxter
McKesson
Mallinckrodt
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.